US20090062371A1 - Oral preparation for promoting synthesis of tissue collagen - Google Patents

Oral preparation for promoting synthesis of tissue collagen Download PDF

Info

Publication number
US20090062371A1
US20090062371A1 US12/280,846 US28084607A US2009062371A1 US 20090062371 A1 US20090062371 A1 US 20090062371A1 US 28084607 A US28084607 A US 28084607A US 2009062371 A1 US2009062371 A1 US 2009062371A1
Authority
US
United States
Prior art keywords
hydroxyproline
oral preparation
salt
collagen
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/280,846
Other languages
English (en)
Inventor
Toshikazu Kamiya
Ayako Kamimura
Yoko Kawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Hakko Bio Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Assigned to KYOWA HAKKO KOGYO CO., LTD. reassignment KYOWA HAKKO KOGYO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAMIMURA, AYAKO, KAMIYA, TOSHIKAZU, KAWADA, YOKO
Publication of US20090062371A1 publication Critical patent/US20090062371A1/en
Assigned to KYOWA HAKKO BIO CO., LTD. reassignment KYOWA HAKKO BIO CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KYOWA HAKKO KOGYO CO., LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
    • A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
    • A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
    • A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds and an oral preparation for preventing or improving skin wrinkles or sagging, which comprise hydroxyproline or a salt thereof as an active ingredient.
  • Collagen is a protein which is the main component of extracellular matrix filling the spaces between cells or groups of cells in living tissues and is said to sometimes comprise nearly 30% of the total protein in the body of mammals (see non-patent document No. 1).
  • Collagen forms a fibrous structure or a membrane structure and its primary function is to maintain, support, bind and reinforce the tissue structure.
  • Collagen exists in abundance in skin, bones, tendons, ligaments, cornea, blood vessels, etc. Decrease and denaturation of tissue collagen is considered to be a major factor for wrinkles, sagging skin, osteoporosis and the like which are induced by aging of these tissues.
  • tissue collagen remarkably decreases by long time exposure to sunlight (see non-patent document No. 2) and that lowering of metabolism of living components accompanying aging is triggered by the lowering of metabolism of collagen (see non-patent document No. 3).
  • Substances known to promote the synthesis of collagen include TGF ⁇ -1, which is a growth factor (see non-patent document No. 4), a plant extract (see patent-document No. 1), hydrolyzed collagen (see patent document Nos. 2 to 5) and an amino acid composition (see patent document No. 6). More specifically, the tripeptide Gly-Pro-Hyp is known as a sequence characteristic of hydrolyzed collagen showing the activity to promote the synthesis of collagen when orally ingested. However, it is also known that an amino acid composition whose constitutive ratio of constituent amino acids such as Gly, Pro and Hyp was made equal to that of collagen does not show the activity to promote the synthesis of collagen (see patent document No. 4).
  • an N-acyl derivative of hydroxyproline is known to have the activity to promote the synthesis of collagen when orally ingested (see non-patent document No. 4), and an external medicine containing an N-acetyl derivative of hydroxyproline is used as a wound-healing agent in Europe. It is also known that hydroxyproline and an N-acyl derivative of hydroxyproline have collagen synthesis promoting effect on cultured human fibroblasts, and when externally applied, they have the activity to prevent or decrease the formation of wrinkles (patent document No. 7). However, unknown are the activity to promote the synthesis of collagen, the activity to promote the healing of skin wounds and the activity to prevent or improve skin wrinkles or sagging of orally ingested hydroxyproline.
  • Patent document No. 1 is a patent document No.
  • An object of the present invention is to provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which is safe and has an excellent effect.
  • the present invention relates to the following (1) to (10).
  • the present invention provides an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, comprising hydroxyproline or a salt thereof as an active ingredient, which is safe and has an excellent effect.
  • FIG. 1 is a graph showing the concentration of free hydroxyproline in serum after oral intake of hydroxyproline.
  • FIG. 2 is a graph showing the concentration of free hydroxyproline in the skin after oral intake of hydroxyproline.
  • Hydroxyproline used in the present invention may be any of the stereoisomers of hydroxyproline. That is, hydroxyproline can exist as eight kinds of stereoisomers according to whether proline is in the D or L form, whether the hydroxyl group is located at the 3- or 4-position, and whether the stereoisomer is in the cis or trans form, and any of these stereoisomers can be employed in the present invention.
  • hydroxyproline includes cis-4-hydroxy-L-proline, cis-4-hydroxy-D-proline, cis-3-hydroxy-L-proline, cis-3-hydroxy-D-proline, trans-4-hydroxy-L-proline, trans-4-hydroxy-D-proline, trans-3-hydroxy-L-proline and trans-3-hydroxy-D-proline.
  • Hydroxyproline is a kind of amino acid which exists widely in nature as the major amino acid component of collagen and as a constituent amino acid of elastin, and can be produced, for example, by acid hydrolysis of collagen derived from animals such as pig and cow, followed by purification by ordinary means.
  • Trans-4-hydroxy-L-proline can be produced by using proline 4-hydroxylase isolated from a microorganism belonging to the genus Amycolatopsis or Dactylosporangium (Japanese Published Unexamined Patent Application No. 313179/95).
  • Cis-3-hydroxy-L-proline can be produced by using praline 3-hydroxylase isolated from a microorganism belonging to the genus Streptomyces (Japanese Published Unexamined Patent Application No. 322885/95) [Bioindustry, Vol. 14, No. 31 (1997)].
  • hydroxyprolines produced by using enzymes derived from microorganisms are superior in quality and are preferred as hydroxyproline used in the present invention.
  • the salts of hydroxyproline include acid addition salts, metal salts, ammonium salts, organic amine addition salts and amino acid addition salts.
  • acid addition salts examples include inorganic acid addition salts such as hydrochloride, sulfate, nitrate and phosphate, and organic acid addition salts such as acetate, maleate, fumarate, citrate, malate, lactate, ⁇ -ketoglutarate, gluconate and caprylate.
  • inorganic acid addition salts such as hydrochloride, sulfate, nitrate and phosphate
  • organic acid addition salts such as acetate, maleate, fumarate, citrate, malate, lactate, ⁇ -ketoglutarate, gluconate and caprylate.
  • metal salts examples include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as magnesium salt and calcium salt, aluminum salt and zinc salt.
  • ammonium salts examples include ammonium salt and tetramethylammonium salt.
  • organic amine addition salts examples include salts with morpholine and piperidine.
  • amino acid addition salts examples include salts with glycine, phenylalanine, lysine, aspartic acid and glutamic acid.
  • the oral preparation for promoting synthesis of tissue collagen, the oral preparation for promoting healing of skin wounds or the oral preparation for preventing or improving skin wrinkles or sagging of the present invention comprises hydroxyproline or a salt thereof, and if necessary, may comprise one or more kinds of pharmaceutically acceptable carriers, and further, active ingredients for other treatments.
  • the oral preparation for promoting synthesis of tissue collagen, the oral preparation for promoting healing of skin wounds or the oral preparation for preventing or improving skin wrinkles or sagging of the present invention can be produced according to arbitrary methods well known in the technical field of pharmaceutics by mixing hydroxyproline or a salt thereof with carriers according to need.
  • additives such as excipients, binders, disintegrating agents, lubricants, dispersants, suspending agents, emulsifiers, diluents, buffers, antioxidants and bacterial inhibitors can be used.
  • the agent of the present invention can be in preparation forms such as tablets, powders, granules, emulsions, syrups and capsules.
  • the preparation form is a liquid preparation such as syrup
  • the preparation can be prepared by adding water, sugars (e.g., sucrose, sorbitol and fructose), glycols (e.g., polyethylene glycol and propylene glycol), oils (e.g., sesame oil, olive oil and soybean oil), antiseptics (e.g., p-hydroxybenzoates), flavors (e.g., strawberry flavor and peppermint), and the like.
  • sugars e.g., sucrose, sorbitol and fructose
  • glycols e.g., polyethylene glycol and propylene glycol
  • oils e.g., sesame oil, olive oil and soybean oil
  • antiseptics e.g., p-hydroxybenzoates
  • flavors e.g., strawberry flavor and peppermint
  • tablets, powders, granules, etc. suitable for oral administration they can be prepared by adding excipients such as sugars (e.g., lactose, white sugar, glucose, sucrose, mannitol and sorbitol), starch (e.g., potato starch, wheat starch and corn starch), inorganic substances (e.g., calcium carbonate, calcium sulfate, sodium hydrogencarbonate and sodium chloride) and plant powders (e.g., licorice powder and gentian powder), disintegrating agents such as starch, agar, gelatin powder, crystalline cellulose, carmellose sodium, carmellose calcium, calcium carbonate, sodium hydrogencarbonate and sodium alginate, lubricants such as magnesium stearate, talc, hydrogenated vegetable oil, macrogol and silicone oil, binders such as polyvinyl alcohol, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, carmellose, gelatin and starch paste, surfact
  • the preparations suitable for oral administration may also comprise additives generally used in foods and drinks such as sweeteners, coloring agents, preservatives, thickening stabilizers, antioxidants, color developers, bleaching agents, fungicides, gum bases, bitter agents, enzymes, glazing agents, sour agents, seasonings, emulsifiers, nutrient supplements, manufacture facilitating agents, flavors and spice extracts.
  • additives generally used in foods and drinks such as sweeteners, coloring agents, preservatives, thickening stabilizers, antioxidants, color developers, bleaching agents, fungicides, gum bases, bitter agents, enzymes, glazing agents, sour agents, seasonings, emulsifiers, nutrient supplements, manufacture facilitating agents, flavors and spice extracts.
  • the preparations suitable for oral administration may be used as such, or in any of the forms such as powder foods, sheet-shaped foods, bottled foods, canned foods, retort pouched foods, capsule foods, tablet foods, liquid foods and health drinks, and may also be used as foods and drinks such as health foods, functional foods, food supplements and foods for specified health uses for promoting synthesis of tissue collagen, promoting healing of skin wounds, or preventing or improving skin wrinkles or sagging.
  • the concentration of hydroxyproline or a salt thereof in the oral preparation of the present invention is appropriately selected depending upon the kind of the oral preparation, the effect expected by the administration of the oral preparation, etc., but it is usually 0.1 to 100% by weight, preferably 0.5 to 70% by weight, particularly preferably 1 to 50% by weight in terms of hydroxyproline or a salt thereof.
  • the dose of the oral preparation of the present invention varies depending upon the administration route, the age and body weight of a subject of administration, etc.
  • the agent is administered in a dose of 5 to 5000 mg, preferably 50 to 5000 mg, more preferably 500 to 5000 mg per day for an adult in terms of hydroxyproline or a salt thereof at once or in several portions.
  • the oral preparation of the present invention can be used not only for humans but also for animals other than humans (hereinafter abbreviated as nonhuman animals).
  • Nonhuman animals include animals other than humans such as mammals, birds, reptiles, amphibians and fish.
  • the dose varies depending upon the age and kind of the animal, etc.
  • the agent is administered once or several times per day in a daily dose of 0.1 to 100 mg, preferably 1 to 100 mg, more preferably 10 to 100 mg per kg of body weight in terms of hydroxyproline or a salt thereof.
  • period of administration There is no specific restriction as to the period of administration, but it is usually one day to one year, preferably one week to three months.
  • HOS HR-1 mouse (seven-week-old female; purchased from Japan SLC, Inc.) was used in the test.
  • Trans-4-hydroxy-L-proline (Kyowa Hakko Kogyo Co., Ltd.; hereinafter referred to as hydroxyproline) was dissolved in purified water at a concentration of 50 mg/ml, and the resulting solution was orally administered in an amount of 500 mg/kg.
  • hydroxyproline was dissolved in purified water at a concentration of 50 mg/ml, and the resulting solution was orally administered in an amount of 500 mg/kg.
  • blood was collected from the abdominal vena cava of the mouse under diethyl ether inhalation anesthesia to obtain a serum.
  • dorsal skin was collected, subjected to freeze-disruption and then to extraction with water to obtain a skin extract.
  • the amount of hydroxyproline in the sera and the skin extract was analyzed by high performance liquid chromatography using ODS column (4.6 cm ⁇ 15 cm, GL Sciences Inc.) after protein was removed with an equal amount of 2% (w/v) sulfosalicylic acid and the second amino group was labeled with NBD-Cl (4-chloro-7-nitro-2,1,3-benzoxadiazole, Tokyo Chemical Industry Co., Ltd.).
  • FIGS. 1 and 2 The results are shown in FIGS. 1 and 2 . It was revealed that the orally ingested hydroxyproline quickly moves into blood and skin.
  • F344/DuCrlCrlj rats (12 heads, 29-week-old male; purchased from Charles River Laboratories Japan, Inc.) were divided into 2 groups each consisting of 6 rats.
  • the rats of Group 1 and Group 2 were fed with the feed of Example 5 and the control feed of Comparative Example 1, respectively, ad libitum for 7 days.
  • the abdominal area of each rat was shaved with clippers under anesthesia by intraperitoneal administration of pentobarbital, and cut sponge pieces (ca. 150 mg, 2 mm thick, ca. 38 mm ⁇ 12 mm; Ivalon, Inc.) were inserted into two spots under the skin, followed by suturing. After further feeding for 7 days, the sponge pieces were taken out.
  • the sponge pieces were subjected to reaction using 6N hydrochloric acid (20 ml/piece) at 110° C. for 18 hours to decompose them with acid and heat.
  • the products obtained by decomposition with acid and heat were diluted 10 times with 1M borate buffer (pH 10.6), and the amount of hydroxyproline was measured in the same manner as in Test Example 1 and was regarded as an index of the collagen-synthesizing ability and tissue-restoring ability of a rat.
  • mice Females aged 47 to 65 years (21 subjects) who chronically suffer from dry skin and rough skin were divided into two groups. After a 2-week observation period, Group 1 (9 subjects) and Group 2 (12 subjects) ingested hard capsules of Example 6 and hard capsules of Comparative Example 2, respectively, for 4 weeks (2 capsules each morning and evening). The test was carried out by parallel-group double-blind test. At the start and the end of the period of ingesting hard capsules, the following questions 1 to 3 were addressed to the subjects (answer “1”: level 1, answer “10”: level 10) and the skin conditions of the subjects were evaluated by a 10-level rating system.
  • Tablets comprising trans-4-hydroxy-L-proline are prepared according to an ordinary method. That is, the following ingredients are uniformly mixed and the resulting mixture is tabletted using a single tablet press to obtain tablets for promoting synthesis of tissue collagen (diameter, 5 mm; weight, 15 mg).
  • Example 1 The tablets obtained in Example 1 are ground, granulated and sieved to obtain granules for promoting healing of skin wounds (20 to 50 mesh).
  • a drink for promoting synthesis of tissue collagen comprising trans-4-hydroxy-L-proline is prepared by uniformly dissolving the following ingredients with stirring and adding purified water to make a total volume of 1000 ml.
  • “Appropriate amount” in the following table refers to an amount used for preparing an ordinary drink in respect of flavor and pigment and refers to an amount necessary to make a total volume of 1000 ml by addition of purified water to the remaining ingredients in respect of purified water.
  • Candies for promoting healing of skin wounds comprising trans-4-hydroxy-L-proline which are composed of the following ingredients are prepared according to an ordinary method.
  • a feed for animals comprising trans-4-hydroxy-L-proline which is composed of the following ingredients was prepared according to an ordinary method.
  • the following ingredients were weighed, put into a mixer and sufficiently mixed to obtain a uniform mixture.
  • the mixture was encapsulated in hard gelatin capsules according to an ordinary method to obtain hard capsules containing trans-4-hydroxy-L-proline (ca. 500 mg/capsule).
  • a feed for animals was prepared using L-aspartic acid in place of trans-4-hydroxy-L-proline of Example 5.
  • Hard capsules were prepared using corn starch in place of trans-4-hydroxy-L-proline of Example 6.
  • the present invention can provide an oral preparation for promoting synthesis of tissue collagen, an oral preparation for promoting healing of skin wounds or an oral preparation for preventing or improving skin wrinkles or sagging, which comprises hydroxyproline or a salt thereof as an active ingredient.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Animal Husbandry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
US12/280,846 2006-03-23 2007-03-23 Oral preparation for promoting synthesis of tissue collagen Abandoned US20090062371A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006079921 2006-03-23
JP079921/06 2006-03-23
PCT/JP2007/055977 WO2007111238A1 (ja) 2006-03-23 2007-03-23 組織コラーゲン合成促進用経口剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/055977 A-371-Of-International WO2007111238A1 (ja) 2006-03-23 2007-03-23 組織コラーゲン合成促進用経口剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/856,566 Division US9433605B2 (en) 2006-03-23 2013-04-04 Method for promoting synthesis of tissue collagen

Publications (1)

Publication Number Publication Date
US20090062371A1 true US20090062371A1 (en) 2009-03-05

Family

ID=38541156

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/280,846 Abandoned US20090062371A1 (en) 2006-03-23 2007-03-23 Oral preparation for promoting synthesis of tissue collagen
US13/856,566 Expired - Fee Related US9433605B2 (en) 2006-03-23 2013-04-04 Method for promoting synthesis of tissue collagen

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/856,566 Expired - Fee Related US9433605B2 (en) 2006-03-23 2013-04-04 Method for promoting synthesis of tissue collagen

Country Status (5)

Country Link
US (2) US20090062371A1 (ja)
EP (1) EP1997490B1 (ja)
JP (1) JP5188388B2 (ja)
CN (1) CN101404998A (ja)
WO (1) WO2007111238A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492494B2 (en) 2007-06-01 2016-11-15 Kyowa Hakko Bio Co., Ltd. Oral composition

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101779733B (zh) * 2010-03-29 2012-12-26 济南环亿生物科技有限公司 一种提高畜禽肌肉中胶原蛋白的饲料添加剂及其生产方法和应用
WO2013137382A1 (ja) * 2012-03-15 2013-09-19 協和発酵バイオ株式会社 骨代謝改善剤
US10400243B2 (en) * 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US6692754B1 (en) * 1999-03-02 2004-02-17 Kyowa Hakko Kogyo Co., Ltd. Cosmetic composition
US20060034781A1 (en) * 2002-11-01 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Peroral preparation for prevention or treatment of atopic dermatatis
US20070293559A1 (en) * 2004-09-21 2007-12-20 Erika Kagami Orally Administered Agent For Preventing Or Improving Dry Station Of Skin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932638A (en) * 1967-09-14 1976-01-13 Franco-Chimie S.A.R.L. Compositions and methods for wound healing
JP3492776B2 (ja) 1993-09-07 2004-02-03 協和醗酵工業株式会社 シス−３−ヒドロキシ−ｌ−プロリンの製造法
JP3122705B2 (ja) 1993-09-07 2001-01-09 協和醗酵工業株式会社 トランス−４−ヒドロキシ−ｌ−プロリンの製造法
JP3782122B2 (ja) 1994-04-11 2006-06-07 サンスター株式会社 経口摂取用新陳代謝促進剤およびそれを配合した食品
FR2770777B1 (fr) * 1997-11-10 2000-02-25 Fabre Pierre Dermo Cosmetique Composition synergique associant de l'acs et/ou de l'adn a de l'hydroxyproline ainsi que leurs applications en nutritherapie et en cosmetologie
JP4023648B2 (ja) 1999-01-13 2007-12-19 日本ハム株式会社 皮膚代謝促進物及び機能性食品
JP3802721B2 (ja) 1999-11-05 2006-07-26 株式会社ファンケル 生体コラーゲン合成促進剤
JP2003137807A (ja) 2001-11-01 2003-05-14 Miyagi Kagaku Kogyo Kk コラーゲン産生促進剤、それを含む化粧品、食品および医薬品ならびに皮膚疾患の予防または改善用外用剤
JP2004035527A (ja) 2002-07-08 2004-02-05 Matsuura Yakugyo Kk コラーゲン合成促進剤
EP1547594A4 (en) * 2002-09-30 2007-08-29 Kyowa Hakko Kogyo Kk PREVENTION OR TREATMENT OF DECUBITUS HORNS
AU2003301761A1 (en) * 2002-10-29 2004-05-25 Medical Nutrition Usa, Inc. Method for treating wounds to promote healing
JP2004315384A (ja) * 2003-04-14 2004-11-11 Kyowa Hakko Kogyo Co Ltd 美白剤
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
JP2006345824A (ja) * 2005-06-20 2006-12-28 Schnee Weisse:Kk 海洋深層水とフカヒレとからなる組成物と該組成物を使用した食品用栄養補助材、化粧品および栄養補助食品
US20070065396A1 (en) * 2005-09-21 2007-03-22 Tracie Martyn International, Llc Topical macqui berry formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827874A (en) * 1995-05-05 1998-10-27 Meyer; Hans Methods of treating pain and inflammation with proline
US6692754B1 (en) * 1999-03-02 2004-02-17 Kyowa Hakko Kogyo Co., Ltd. Cosmetic composition
US20060034781A1 (en) * 2002-11-01 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Peroral preparation for prevention or treatment of atopic dermatatis
US20070293559A1 (en) * 2004-09-21 2007-12-20 Erika Kagami Orally Administered Agent For Preventing Or Improving Dry Station Of Skin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492494B2 (en) 2007-06-01 2016-11-15 Kyowa Hakko Bio Co., Ltd. Oral composition

Also Published As

Publication number Publication date
WO2007111238A1 (ja) 2007-10-04
EP1997490A1 (en) 2008-12-03
EP1997490B1 (en) 2018-05-02
JPWO2007111238A1 (ja) 2009-08-13
EP1997490A4 (en) 2013-07-31
US9433605B2 (en) 2016-09-06
US20130225650A1 (en) 2013-08-29
CN101404998A (zh) 2009-04-08
JP5188388B2 (ja) 2013-04-24

Similar Documents

Publication Publication Date Title
US10052298B2 (en) Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine
EA010098B1 (ru) Неперевариваемые in vivo пептиды, имеющие активность ингибитора ангиотензинпревращающего фермента, лекарственное средство и пищевой продукт
RU2526199C2 (ru) Композиция, способствующая выработке коллагена
JP2001048789A (ja) 美肌促進剤及び美容健康食品
MX2009001783A (es) Compuestos heterociclicos como potenciadores de edulcorantes.
US9433605B2 (en) Method for promoting synthesis of tissue collagen
JPH07278012A (ja) 新陳代謝促進剤およびそれを配合した食品
US8067537B2 (en) Composition and method for treatment of stomatitis
KR20070095338A (ko) 간기능 개선제
JP2008519758A (ja) 抗糖尿病作用を有する蛋白加水分解物
US7485662B2 (en) Therapeutic agent for diabetes mellitus
JP2005211078A (ja) 美容健康食品
JP5885784B2 (ja) 経口組成物
US20190183811A1 (en) Composition containing squalene for improving muscle function and preventing muscle damage
US6919306B2 (en) Method of skin care
WO2020235900A1 (ko) 골 손실 질환의 예방, 개선 또는 치료를 위한 chp(사이클로-히스프로) 및 부갑상선 호르몬을 포함하는 조성물의 용도
WO2021193820A1 (ja) 毛髪の太毛化促進用組成物、毛周期の成長期維持用組成物およびｖｅｇｆ産生促進用組成物、毛周期の休止期から成長期への移行促進用組成物およびｆｇｆ７産生促進用組成物、ならびに毛周期の正常化促進用組成物
JP2008278891A (ja) 美容健康食品

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYOWA HAKKO KOGYO CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KAMIYA, TOSHIKAZU;KAWADA, YOKO;KAMIMURA, AYAKO;REEL/FRAME:021455/0305;SIGNING DATES FROM 20080806 TO 20080808

AS Assignment

Owner name: KYOWA HAKKO BIO CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KYOWA HAKKO KOGYO CO., LTD.;REEL/FRAME:022578/0259

Effective date: 20081001

Owner name: KYOWA HAKKO BIO CO., LTD.,JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KYOWA HAKKO KOGYO CO., LTD.;REEL/FRAME:022578/0259

Effective date: 20081001

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION